Skip to content
← Resources / Articles
Carve-outs5 min read

What a $48.7bn deal teaches you about selling a carved-out business

Kimberly-Clark did not buy a division of Johnson & Johnson. It bought a company that spent two years being built out of one, and that is the difference between a carve-out that sells and a carve-out that sits. The sequence matters more than the price.

All M&A Research

Carve-outs and separations

Updated
A grocery store aisle lined with metal shelves of packaged household and personal care products.
A grocery store aisle lined with metal shelves of packaged household and personal care products.

Key takeaways

  • Johnson & Johnson took roughly two years to turn its consumer health division into Kenvue: announced November 2021, assets transferred April 2023, listed May 2023, separation completed August 2023.
  • Kimberly-Clark then bought the finished company for an enterprise value of about $48.7bn, agreed in November 2025 and completed in November 2026.
  • The buyer paid for a standalone business, not a division. Everything that made it standalone was built during the separation, by the seller, before any buyer was in the room.
  • The same sequence applies at £10m. A division that has never had its own accounts, contracts or management is worth less than one that has, and the gap is wider than most sellers expect.

Most of the coverage of Kimberly-Clark’s purchase of Kenvue treated it as a consumer goods story: Kleenex and Huggies meeting Tylenol and Neutrogena, with about $2.1bn of promised run-rate synergies to justify the cheque. That is the business story. The transaction story is more useful to anyone who will one day sell part of their own company, and it has almost nothing to do with the price.

Kimberly-Clark did not buy a division of Johnson & Johnson. By the time it signed, there was no division to buy. It bought a listed company with its own balance sheet, its own management, its own auditors and its own supply contracts, and every one of those things had been constructed, at J&J’s expense and on J&J’s timetable, in the two years before Kimberly-Clark arrived.

The separation was a transaction of its own

The timeline is worth setting out plainly, because the length of it is the point.

DateWhat happened
November 2021J&J announces its intention to separate the consumer health business
April 2023J&J transfers substantially all of the assets and liabilities of the consumer health business to Kenvue
May 2023Kenvue lists on the NYSE at $22.00 a share
August 2023J&J completes an exchange offer covering 80.1% of Kenvue’s stock, completing the separation
November 2025Kimberly-Clark agrees to acquire Kenvue
November 2026The acquisition completes

Roughly two years from announcement to a separated company, and another three before a buyer took the whole thing. Nobody paid J&J a fee for the first two years. There was no purchase agreement for that work and no closing date. It was, as the phrase goes, two transactions wearing one signature page: except here they were years apart, and the second one was only possible because the first had been finished.

A buyer can pay for a business. It cannot pay for a business that does not yet exist as a business.

What the buyer was actually buying

Look at what Kimberly-Clark agreed to pay. The headline enterprise value of about $48.7bn was struck against Kimberly-Clark’s own share price on 31 October 2025, which put the consideration at roughly $21.01 for each Kenvue share: $3.50 in cash plus 0.14625 of a Kimberly-Clark share. On completion the company issued around 281.1 million of its own shares and paid approximately $6.7bn in cash.

That is a conventional cash-and-stock structure, and it was only available because the target was a conventional company. You can agree a fixed exchange ratio against a listed entity with audited accounts. You cannot agree one against a set of allocated management accounts and a promise to extract the business later.

The regulators treated it as a company too. The European Commission cleared the deal subject to remedies, with Kimberly-Clark agreeing to divest certain feminine hygiene brands in the European Economic Area. The kind of condition you can only impose, and only satisfy, when the assets are already ring-fenced and saleable on their own.

The same thing happens at £10m, without the press release

None of this is a mega-deal phenomenon. It is the ordinary mechanics of selling a division, and it shows up in every size of transaction.

When an owner decides to sell one site, one product line or one subsidiary, the business being sold usually has:

  • No accounts of its own. It has an allocation of the group’s accounts, which is not the same thing and will not survive diligence intact.
  • No contracts in its own name. The software, the insurance, the logistics agreement and often the largest customer contract sit at group level, on group pricing.
  • No management. The person who runs it also runs two other things, and is not necessarily coming with it.
  • No working capital position of its own. Which becomes an argument the moment anyone has to agree a working capital peg, because there is no clean history to set it against.

A buyer facing that will do one of three things: discount the price for the work and risk, slow the deal down while it quantifies them, or walk. All three cost the seller money. J&J spent two years and considerable expense avoiding all three.

What that means if you are the seller

The uncomfortable conclusion is that the cheapest moment to do separation work is before you are in a process, when you are not negotiating against a deadline and nobody is reading your answers as a concession.

In practice that means knowing, before you go to market: what the business actually costs to run when nobody else is paying for anything; which contracts have to be re-papered and at what price; who has to transfer and who has to be hired; and what a normal level of working capital looks like for it as a standalone operation.

That is unglamorous work, and it is the work that decides whether you are selling a company or selling a project. Kimberly-Clark paid $48.7bn for a company. Nobody would have paid that for a project.

Sources

The figures and dates above come from the parties’ own filings and announcements. Deal values and status for current transactions are tracked by M&A News, which lists every merger and acquisition above $250m announced this year.

  • Kenvue Inc., Annual Report on Form 10-K for FY2023: separation timeline, the April 2023 asset transfer, the August 2023 exchange offer covering 80.1% of the stock, and J&J’s retained holding.
  • Kimberly-Clark Corporation, Quarterly Report on Form 10-Q, FY2026: cash consideration of approximately $6.7bn and approximately 281.1 million shares issued on completion.
  • Kimberly-Clark and Kenvue transaction announcement, 3 November 2025: enterprise value of approximately $48.7bn, per-share consideration of $3.50 in cash plus 0.14625 Kimberly-Clark shares, struck on Kimberly-Clark’s closing price of 31 October 2025, and expected run-rate synergies of approximately $2.1bn.
  • European Commission merger clearance: conditional approval with a divestment of certain feminine hygiene brands in the European Economic Area.